drugset
drugset / Trial / NCT04291300

Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients

NCT04291300 ↗

Phase 2 Completed 12 enrolled Radboud University Medical Center Dutch Cancer Society · collab
NaSingle-groupOpen-labelTreatment

Summary

Phase 2 pilot study, which evaluates the safety and efficacy of Lutetium-177-PSMA radioligand therapy in advanced salivary gland cancer patients.

Timeline

Start
2020-05-26
Primary completion
2023-02-13
Completion
2023-02-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Lutetium-177 PSMA-I&T Other / unclassified 7400 mbq Intravenous

Indications

adenoid cystic carcinoma salivary duct carcinoma